Aptar Reports First Quarter 2026 Results

Key Terms

biologics medical

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

adjusted ebitda margin financial

Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.

effective tax rate financial

The effective tax rate is the percentage of a company's profits that it pays in taxes. It shows how much of its earnings go to taxes after all deductions and credits are considered. For investors, it indicates how much of the company's income is taken by taxes, impacting overall profitability and financial health.

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year.

Aptar Reports First Quarter 2026 Results

First Quarter 2026 Highlights

(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)

• Reported sales increased 11% and core sales were flat
• Reported net income decreased 8% to $73 million and reported earnings per share decreased 4% to $1.12
• Adjusted earnings per share were $1.19, a decrease of 8%, compared to the prior year at constant currency
• Adjusted EBITDA margin was 19.2% compared to 20.7% in the prior year
• Returned $131 million to shareholders through share repurchases and dividends
• Gael Touya named Aptar’s next CEO effective September 1, 2026

“Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP‑1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing, and active material solutions. As anticipated, first quarter results were impacted by emergency medicine destocking, with comparisons further challenged by the exceptionally strong prior-year quarter for the prescription division. The injectables division delivered another quarter of strong, double-digit growth. Consumer dispensing also contributed positively, with volume growth across Beauty and Closures, supported by robust demand in prestige fragrance and beverage applications,” said Stephan B. Tanda, Aptar President and CEO.

First Quarter Results

For the quarter ended March 31, 2026, reported sales increased 11% to $982.9 million compared to $887.3 million in the prior year period. Core sales were flat compared to the prior year period.

First Quarter Segment Sales Analysis (Change Over Prior Year)
	Pharma	Beauty	Closures	Total AptarGroup
Reported Sales Growth	7%	19%	5%	11%
Currency Effects (1)	(7)%	(9)%	(5)%	(8)%
Acquisitions	(1)%	(7)%	0%	(3)%
Core Sales Growth	(1)%	3%	0%	0%
(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Pharma’s reported sales increased 7% when compared to the prior year period, with a currency contribution of 7%. Excluding acquisitions, core sales declined 1% in the quarter when compared to the prior year period. In the prescription division, sales for dispensing systems declined 10% primarily due to reduced sales in the emergency medicine category, as anticipated, while the pipeline for systemic nasal drug delivery continued to build. Consumer healthcare sales increased 4% on strong nasal decongestant and eye care solutions. Sales in the injectables division increased 20%, mainly driven by growth in demand for elastomeric components used for GLP-1, biologics and antithrombotics. Active material science solutions declined 1% due primarily to lower sales for diabetes test strips and probiotics. Adjusted EBITDA margin was 33.3%, a decrease of 150 basis points, reflecting a less favorable product mix, while royalties continued to positively impact margins.

Beauty’s reported sales increased 19% when compared to the prior year period, driven by a 9% benefit from currency changes and a 7% contribution from acquisitions, with core sales growth of 3%. There was increased demand for fragrance dispensing, as well as hair care and body care applications. Adjusted EBITDA margin was 11.1%, a decline of 100 basis points, due to less favorable product mix, primarily in North America and isolated operational disruptions at a supplier as reported last quarter.

Closures’ reported sales rose 5% from the prior year quarter and core sales were flat, with a 5% currency benefit. While product volumes were up, core sales results were negatively impacted by the pass through of lower resin pricing. Adjusted EBITDA margin was 13.1%, a decline of 270 basis points, primarily due to the previously reported maintenance issues, temporary plant closures as a result of extreme weather in North America and certain investment write offs.

Reported first quarter earnings per share were $1.12 compared to $1.17 reported a year ago. Adjusted earnings per share were $1.19, compared to the prior year period’s adjusted earnings per share of $1.30, including comparable exchange rates. The first quarter reported effective tax rate was 22.4% and the adjusted effective tax rate was 22.6%, compared to the prior year period’s reported and adjusted effective tax rates of 25.8%.

Outlook

Regarding Aptar’s outlook, Tanda stated, “Looking ahead to Q2, excluding destocking in emergency medicine within Pharma, we anticipate a solid quarter with growth across each segment. Outside of the emergency medicine end market, our prescription division is expected to return to healthy growth, and we anticipate growth across a number of pharma end markets mainly due to strength in our injectables and consumer healthcare divisions. We also anticipate a strong quarter for Closures and continued growth in Beauty, particularly in fragrance. Heading into the quarter, we remain mindful of potential supply‑chain uncertainties as we continue to operate in a dynamic environment.”

Aptar currently expects adjusted earnings per share for the second quarter of 2026 to be in the range of $1.32 to $1.40. This guidance assumes an effective tax rate range of 22.5% to 24.5%. The earnings per share guidance range is assuming a 1.18 Euro to USD exchange rate.

Cash Dividends and Share Repurchases

As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026. During the first quarter, Aptar repurchased 707 thousand shares for $100 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

Open Conference Call

There will be a conference call held on Friday, May 1, 2026 at 8:00 a.m. Central Time to discuss the company’s first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug delivery and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 14,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. For the quarter ended March 31, 2026, “Other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring, acquisition costs and other special items.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; competition, including technological advances; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

AptarGroup, Inc. Condensed Consolidated Financial Statements (Unaudited) (In Thousands, Except Per Share Data) Consolidated Statements of Income
	Three Months Ended March 31,
	2026				2025
Net Sales	$	982,868			$	887,305
Cost of Sales (exclusive of depreciation and amortization shown below)		630,959				550,891
Selling, Research & Development and Administrative		167,602				155,277
Depreciation and Amortization		75,725				65,647
Restructuring Initiatives		1,086				2,042
Operating Income		107,496				113,448
Other Income (Expense):
Interest Expense		(16,942	)			(11,351	)
Interest Income		3,642				2,814
Net Investment Loss		(1,086	)			(1,096	)
Equity in Results of Affiliates		714				2,086
Miscellaneous (Expense) Income, net		(53	)			114
Income before Income Taxes		93,771				106,015
Provision for Income Taxes		21,004				27,352
Net Income	$	72,767			$	78,663
Net (Income) Loss Attributable to Noncontrolling Interests		(4	)			135
Net Income Attributable to Redeemable Noncontrolling Interests		(89	)			—
Net Income Attributable to AptarGroup, Inc.	$	72,674			$	78,798
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic	$	1.13			$	1.19
Diluted	$	1.12			$	1.17
Average Numbers of Shares Outstanding:
Basic		64,050				66,271
Diluted		64,834				67,491

AptarGroup, Inc. Condensed Consolidated Financial Statements (Unaudited) (continued) ($ In Thousands) Consolidated Balance Sheets
	March 31, 2026				December 31, 2025
ASSETS
Cash and Equivalents	$	222,529			$	402,424
Short-term Investments		6,948				7,109
Accounts and Notes Receivable, Net		833,268				803,830
Inventories		551,482				537,845
Prepaid and Other		154,045				142,354
Total Current Assets		1,768,272				1,893,562
Property, Plant and Equipment, Net		1,660,929				1,676,479
Goodwill		1,072,560				1,077,898
Other Assets		596,022				604,780
Total Assets	$	5,097,783			$	5,252,719
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY
Short-Term Obligations	$	222,166			$	343,531
Accounts Payable, Accrued and Other Liabilities		840,867				822,913
Total Current Liabilities		1,063,033				1,166,444
Long-Term Obligations		1,143,370				1,139,433
Deferred Liabilities and Other		217,129				234,617
Total Liabilities		2,423,532				2,540,494
Redeemable Noncontrolling Interests		26,694				26,244
Total Mezzanine Equity		26,694				26,244
AptarGroup, Inc. Stockholders' Equity		2,629,495				2,668,096
Noncontrolling Interests in Subsidiaries		18,062				17,885
Total Stockholders' Equity		2,647,557				2,685,981
Total Liabilities, Mezzanine Equity and Stockholders' Equity	$	5,097,783			$	5,252,719

AptarGroup, Inc. Condensed Consolidated Financial Statements (Unaudited) (continued) ($ In Thousands) Consolidated Statement of Cash Flows
Three Months Ended March 31,	2026				2025
Cash Flows from Operating Activities:	​				​
Net income	$	72,767			$	78,663
Adjustments to reconcile net income to net cash provided by operations:
Depreciation		64,310				54,903
Amortization		11,415				10,744
Stock-based compensation		16,764				19,193
Provision for CECL		644				35
Loss (gain) on disposition of fixed assets		81				(271	)
Net loss on remeasurement of equity securities		1,086				1,096
Deferred income taxes		(4,567	)			(1,860	)
Defined benefit plan expense		3,443				3,277
Equity in results of affiliates		(714	)			(2,086	)
Impairment loss		901				—
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables		(33,030	)			(69,247	)
Inventories		(16,943	)			(6,043	)
Prepaid and other current assets		(12,393	)			(12,617	)
Accounts payable, accrued and other liabilities		36,422				33,324
Income taxes payable		103				(7,195	)
Retirement and deferred compensation plan		(15,271	)			(11,751	)
Other changes, net		(6,324	)			(7,423	)
Net Cash Provided by Operations		118,694				82,742
Cash Flows from Investing Activities:
Capital expenditures		(65,396	)			(56,862	)
Proceeds from sale of property, plant and equipment		1,327				79
Purchases of short-term investments, net		(103	)			(88	)
Acquisition of intangible assets, net		(592	)			(2,475	)
Notes receivable, net		(335	)			2,714
Net Cash Used by Investing Activities		(65,099	)			(56,632	)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts		2,930				79
Repayments of notes payable and overdrafts		(2,895	)			—
Proceeds and (repayments) of short term revolving credit facility, net		7,000				(23,880	)
Proceeds from long-term obligations		5,037				124
Repayments of long-term obligations		(127,927	)			(4,552	)
Payment of contingent consideration obligation		(2,197	)			—
Dividends paid		(30,920	)			(29,923	)
Proceeds from stock option exercises		18,516				3,375
Purchase of treasury stock		(99,973	)			(80,000	)
Redeemable noncontrolling interest		89				—
Net Cash Used by Financing Activities		(230,340	)			(134,777	)
Effect of Exchange Rate Changes on Cash		(3,150	)			10,662
Net Decrease in Cash and Equivalents and Restricted Cash		(179,895	)			(98,005	)
Cash and Equivalents and Restricted Cash at Beginning of Period		404,849				223,844
Cash and Equivalents and Restricted Cash at End of Period	$	224,954			$	125,839

AptarGroup, Inc. Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
	Three Months Ended March 31, 2026
	Consolidated					Pharma				Beauty				Closures				Corporate & Other				Net Interest
Net Sales	$	982,868				$	438,560			$	363,635			$	180,673			$	—			$	—
Reported net income	$	72,767
Reported income taxes		21,004
Reported income before income taxes		93,771					106,658				14,458				9,184				(23,229	)			(13,300	)
Adjustments:
Restructuring initiatives		1,086					5				1,301				249				(469	)
Net investment loss		1,086					—				—				—				1,086
Transaction costs related to acquisitions		45					45				—				—				—
Purchase accounting adjustments related to acquisitions and investments		145					145				—				—				—
Other special items		3,727					3,727				—				—				—
Adjusted earnings before income taxes		99,860					110,580				15,759				9,433				(22,612	)			(13,300	)
Interest expense		16,942																					16,942
Interest income		(3,642	)																				(3,642	)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		113,160					110,580				15,759				9,433				(22,612	)			—
Depreciation and amortization		75,725					35,643				24,723				14,224				1,135
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	188,885				$	146,223			$	40,482			$	23,657			$	(21,477	)		$	—
Reported net income margins (Reported net income / Reported Net Sales)		7.4	%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		19.2	%				33.3	%			11.1	%			13.1	%

	Three Months Ended March 31, 2025
	Consolidated					Pharma				Beauty				Closures				Corporate & Other				Net Interest
Net Sales	$	887,305				$	409,467			$	305,707			$	172,131			$	—			$	—
Reported net income	$	78,663
Reported income taxes		27,352
Reported income before income taxes		106,015					111,112				16,681				12,333				(25,574	)			(8,537	)
Adjustments:
Restructuring initiatives		2,042					190				395				1,352				105
Net investment loss		1,096					—				—				—				1,096
Adjusted earnings before income taxes		109,153					111,302				17,076				13,685				(24,373	)			(8,537	)
Interest expense		11,351																					11,351
Interest income		(2,814	)																				(2,814	)
Adjusted earnings before net interest and taxes (Adjusted EBIT)		117,690					111,302				17,076				13,685				(24,373	)			—
Depreciation and amortization		65,647					31,148				20,062				13,575				862				—
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)	$	183,337				$	142,450			$	37,138			$	27,260			$	(23,511	)		$	—
Reported net income margins (Reported net income / Reported Net Sales)		8.9	%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)		20.7	%				34.8	%			12.1	%			15.8	%

AptarGroup, Inc. Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) (In Thousands, Except Per Share Data)
	Three Months Ended March 31,
	2026				2025
Income before Income Taxes	$	93,771			$	106,015
Adjustments:
Restructuring initiatives		1,086				2,042
Net investment loss		1,086				1,096
Transaction costs related to acquisitions		45				—
Purchase accounting adjustments related to acquisitions and investments		145				—
Other special items		3,727				—
Foreign currency effects (1)						8,992
Adjusted Earnings before Income Taxes	$	99,860			$	118,145
Provision for Income Taxes	$	21,004			$	27,352
Adjustments:
Restructuring initiatives		279				506
Net investment loss		266				269
Transaction costs related to acquisitions		11				—
Purchase accounting adjustments related to acquisitions and investments		49				—
Other special items		953				—
Foreign currency effects (1)						2,320
Adjusted Provision for Income Taxes	$	22,562			$	30,447
Net (Income) Loss Attributable to Noncontrolling Interests	$	(4	)		$	135
Net Income Attributable to Redeemable Noncontrolling Interests	$	(89	)		$	—
Net Income Attributable to AptarGroup, Inc.	$	72,674			$	78,798
Adjustments:
Restructuring initiatives		807				1,536
Net investment loss		820				827
Transaction costs related to acquisitions		34				—
Purchase accounting adjustments related to acquisitions and investments		96				—
Other special items		2,774				—
Foreign currency effects (1)						6,672
Adjusted Net Income Attributable to AptarGroup, Inc.	$	77,205			$	87,833
Average Number of Diluted Shares Outstanding		64,834				67,491
Net Income Attributable to AptarGroup, Inc. Per Diluted Share	$	1.12			$	1.17
Adjustments:
Restructuring initiatives		0.01				0.02
Net investment loss		0.01				0.01
Transaction costs related to acquisitions		—				—
Purchase accounting adjustments related to acquisitions and investments		—				—
Other special items		0.05				—
Foreign currency effects (1)						0.10
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share	$	1.19			$	1.30
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.

AptarGroup, Inc. Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) (In Thousands)
	Three Months Ended March 31,
	2026				2025
Net Cash Provided by Operations	$	118,694			$	82,742
Capital Expenditures		(65,396	)			(56,862	)
Free Cash Flow	$	53,298			$	25,880

AptarGroup, Inc. Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) (In Thousands, Except Per Share Data)
	Three Months Ending June 30,
	Expected 2026		2025
Income before Income Taxes			$	139,714
Adjustments:
Restructuring initiatives				1,579
Net investment gain				(2,102	)
Transaction costs related to acquisitions				344
Foreign currency effects (1)				919
Adjusted Earnings before Income Taxes			$	140,454
Provision for Income Taxes			$	27,982
Adjustments:
Restructuring initiatives				421
Net investment gain				(515	)
Transaction costs related to acquisitions				86
Foreign currency effects (1)				184
Adjusted Provision for Income Taxes			$	28,158
Net Income Attributable to Noncontrolling Interests			$	(12	)
Net Income Attributable to AptarGroup, Inc.			$	111,720
Adjustments:
Restructuring initiatives				1,158
Net investment gain				(1,587	)
Transaction costs related to acquisitions				258
Foreign currency effects (1)				735
Adjusted Net Income Attributable to AptarGroup, Inc.			$	112,284
Average Number of Diluted Shares Outstanding				67,048
Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3)			$	1.67
Adjustments:
Restructuring initiatives				0.02
Net investment gain				(0.03	)
Transaction costs related to acquisitions				—
Foreign currency effects (1)				0.01
Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)	$1.32 - $1.40		$	1.67
(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.
(2) AptarGroup’s expected adjusted earnings per share range for the second quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 22.5% to 24.5%. This tax rate range compares to our second quarter of 2025 effective tax rate of 20.0% on both reported and adjusted earnings per share.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430601030/en/

Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
815-479-5530

Media Contact:
Katie Reardon
katie.reardon@aptar.com
815-479-5671

Source: AptarGroup, Inc.